POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

FDA approves Comirnaty, first COVID-19 brand name approved in U.S.

Christian Fernsby |
Brand Institute announced its role in naming Pfizer and BioNTech's FDA-approved COVID-19 vaccine: Comirnaty.

Article continues below

The brand name has also been approved by regulators in Japan and Australia, among other countries.

"The entire Brand Institute and Drug Safety Institute Team congratulates Pfizer and BioNTech on the FDA approval of Comirnaty," said Brand Institute's Chairman and CEO, James L. Dettore.

"This approval is a critically important step in the fight against COVID-19 and communicates to the public that the agency's high standards of efficacy and safety have been met."

FDA approval of a pharmaceutical or vaccine product's brand name is also a significant step toward the development of a global brand.

"Developing a global brand name is an increasingly challenging endeavor as global health agencies employ an intensive review of proposed drug names with the goal of minimizing medication errors and ensuring patient safety," Dettore said. "We are honored to have developed a name that is fulfilling the requirements for approval set forth by global health authorities including the FDA."

The COVID-19 vaccine's nonproprietary name (INN), tozinameran, was also developed by Brand Institute and its wholly owned subsidiary, Drug Safety Institute.

What to read next

EMA advises use of Pfizer vaccine for 12-15 year olds
EMA starts evaluating use of COVID-19 vaccine Comirnaty in young people
Dramatic increase in e-cigarette use among youth in U.S.